BIOMAT Database Logo BIOMAT Database Logo

Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. 1993

H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
University of Louisville School of Medicine, Kentucky.

A randomized prospective trial was undertaken in adult patients with serious intra-abdominal infections to determine whether a new combination of antibiotic therapy could prove as efficacious as the combination that has been widely used in practice in the recent decade (clindamycin and gentamicin). Three hundred thirty-one patients were randomized in a 2:1 ratio, with the larger number of patients being treated parenterally with piperacillin and tazobactam. The results showed that both the clinical and microbiologic performance of the piperacillin/tazobactam combination was better than that of clindamycin and gentamicin. This clinical equivalence permits overall cost savings without compromising the existing quality of antimicrobial therapy for intra-abdominal infection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010397 Penicillanic Acid A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed) Acid, Penicillanic
D010538 Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs. Primary Peritonitis,Secondary Peritonitis,Peritonitis, Primary,Peritonitis, Secondary
D010878 Piperacillin Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics. AB-Piperacillin,Cl-227193,Pipcil,Pipera-Hameln,Piperacillin Curasan,Piperacillin Fresenius,Piperacillin Hexal,Piperacillin Monosodium Salt,Piperacillin Sodium,Piperacillin-Ratiopharm,Pipercillin,Pipracil,Pipril,T-1220,T1220,AB Piperacillin,Cl 227193,Cl227193,Curasan, Piperacillin,Monosodium Salt, Piperacillin,Pipera Hameln,Piperacillin Ratiopharm,Salt, Piperacillin Monosodium,Sodium, Piperacillin,T 1220
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002761 Cholangitis Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both. Cholangitides
D002764 Cholecystitis Inflammation of the GALLBLADDER; generally caused by impairment of BILE flow, GALLSTONES in the BILIARY TRACT, infections, or other diseases. Empyema, Gallbladder,Gallbladder Inflammation,Empyema, Gall Bladder,Gall Bladder Empyema,Gallbladder Empyema,Inflammation, Gallbladder
D002981 Clindamycin An antibacterial agent that is a semisynthetic analog of LINCOMYCIN. 7-Chloro-7-deoxylincomycin,Chlolincocin,Chlorlincocin,Cleocin,Clindamycin Hydrochloride,Clindamycin Monohydrochloride,Clindamycin Monohydrochloride, Monohydrate,Dalacin C,7 Chloro 7 deoxylincomycin,Hydrochloride, Clindamycin,Monohydrate Clindamycin Monohydrochloride,Monohydrochloride, Clindamycin,Monohydrochloride, Monohydrate Clindamycin
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.
January 1994, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement,
H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection.
July 2004, Asian journal of surgery,
H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
Piperacillin-tazobactam treatment for severe intra-abdominal infections.
January 1995, Acta chirurgica Belgica,
H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
January 1993, The Journal of antimicrobial chemotherapy,
H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.
March 2008, The Journal of antimicrobial chemotherapy,
H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
January 2001, PharmacoEconomics,
H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.
January 1994, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement,
H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
August 2005, The Journal of antimicrobial chemotherapy,
H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
The treatment of severe intra-abdominal infections: the role of piperacillin/tazobactam.
July 1994, Intensive care medicine,
H C Polk, and M P Fink, and M Laverdiere, and S E Wilson, and G E Garber, and P S Barie, and J C Hebert, and W G Cheadle
Efficacy of piperacillin/tazobactam in the treatment of experimental intra-abdominal infections.
January 1994, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement,
Copied contents to your clipboard!